The estimated Net Worth of Raymond Huggenberger is at least $1.39 Million dollars as of 15 September 2021. Mr. Huggenberger owns over 4,000 units of Inogen Inc stock worth over $249,499 and over the last 11 years he sold INGN stock worth over $913,031. In addition, he makes $225,022 as Independent Director at Inogen Inc.
Raymond has made over 48 trades of the Inogen Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 4,000 units of INGN stock worth $154,160 on 15 September 2021.
The largest trade he's ever made was exercising 165,891 units of Inogen Inc stock on 3 November 2014 worth over $398,138. On average, Raymond trades about 14,865 units every 39 days since 2014. As of 15 September 2021 he still owns at least 21,583 units of Inogen Inc stock.
You can see the complete history of Mr. Huggenberger stock trades at the bottom of the page.
Raymond O. Huggenberger is Independent Director of Inogen, Inc. Mr. Huggenberger previously served as our Chief Executive Officer from 2008 until March 1, 2017 and as our President from 2008 until January 1, 2016. Prior to joining our company, Mr. Huggenberger held various management positions with Sunrise Medical Inc., a global manufacturer and distributor of durable medical equipment, including: Vice President of Marketing for Sunrise’s German subsidiary from 1994 to 1996, President of Sunrise’s German division from 1998 until 2000, President of the European Operating Group from 2000 to 2002, President and Chief Operating Officer from 2002 until 2004, and President of European Operations 2006 to 2007. Mr. Huggenberger also held a consultant position with McDermott and Bull Inc., an executive search firm, from 2005 to 2006 and the position of Managing Director in the healthcare division of TA Triumph Adler AG, a document process management firm, from 1996 to 1998. Mr. Huggenberger currently serves on the Board of Directors of Tactile Systems Technology Inc., a publicly traded company, Clarify Medical Inc., Ebb Therapeutics, and Sommetrics, Inc., which are all medical device companies, as well as Intricon Corporation, a medical technology company. Mr. Huggenberger graduated from AKAD University in Rendsburg, Germany in Economics and completed the Advanced Marketing Strategies Program at INSEAD, Fontainebleau, France. The Board believes that he is qualified to serve as a director of Inogen because of his deep understanding of our business, operations and strategy and extensive executive and director roles with healthcare companies.
As the Independent Director of Inogen Inc, the total compensation of Raymond Huggenberger at Inogen Inc is $225,022. There are 13 executives at Inogen Inc getting paid more, with Scott Wilkinson having the highest compensation of $2,520,530.
Raymond Huggenberger is 61, he's been the Independent Director of Inogen Inc since 2017. There are 1 older and 15 younger executives at Inogen Inc. The oldest executive at Inogen Inc is Benjamin Anderson-Ray, 65, who is the Independent Director.
Raymond's mailing address filed with the SEC is 3701 WAYZATA BLVD., SUITE 300, MINNEAPOLIS, MN, 55416.
Over the last 11 years, insiders at Inogen Inc have traded over $242,179,025 worth of Inogen Inc stock and bought 9,125 units worth $253,950 . The most active insiders traders include Holdings A/S Novo, Timothy Petersen und Raymond Huggenberger. On average, Inogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $321,391. The most recent stock trade was executed by Jason Somer on 1 June 2024, trading 577 units of INGN stock currently worth $6,670.
inogen’s mission to improve the quality of life of supplemental oxygen users began in 2001 when mae, a beloved grandmother, was prescribed oxygen therapy. learn more about mae’s story here: http://www.inogen.com/about-inogen/meet-mae/. inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. we estimate that more than 2.5 million patients in the united states and more than 4.5 million patients worldwide use oxygen therapy. our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. we believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. with each step we take to improve our products and service, our customers take
Inogen Inc executives and other stock owners filed with the SEC include: